In case you missed it: our Chief Strategy Officer Mirja Riester and Digital Developer Crystal Gaskin shared insights from a successful case study on how to meaningfully and effectively engage underserved patient populations. Learn how our research-driven approach built trust and credibility in the community with the goal of transforming patient perceptions of long-term disease management. Plus, see how we can apply these insights to other underserved patient populations. You can catch the full presentation here: bit.ly/3KAe6VA #DigitalPharmaInnovationWeek Fierce Pharma #PharmaMarketing
RiesterRx’s Post
More Relevant Posts
-
RDDT: We have SOLVED the Rare Disease diagnostic odyssey PROBLEM with a compliant commercial patient centric SOLUTION, that closes a WIDE care gap for PROVIDERS and generates important new revenue for HEALTHCARE
Healthcare is a volume and value focused business model, and proactively looking for lost and undiagnosed rare disease patients, is at the bottom of that to do list! And if you aren't looking, I can promise you aren't finding too well! (see 5-8 year diagnostic odyssey across all rare disease patient populations, 1 in 10 people or 30+million US patients). We (RDDT) solve this volume bias problem for healthcare in rare diseases! #rarediseases
-
-
Dr. Kapil Raina, Brian Williams, and Chris Zealey share launch planning best practices for rare disease therapies, including budgeting, resource allocation, and stakeholder engagement strategies: https://lnkd.in/eSa2tdzX #AskHerspiegel #CommercialConversation #RareDisease #LaunchPlan
-
-
Dr. Kapil Raina, Brian Williams, and Chris Zealey share launch planning best practices for rare disease therapies, including budgeting, resource allocation, and stakeholder engagement strategies: https://bit.ly/4i5I5nW #AskHerspiegel #CommercialConversation #RareDisease #LaunchPlan
-
-
Exciting news for myositis research! At the first Myositis Common Data Elements (CDE) Consensus Conference, global experts worked to standardize tools for collecting patient data, paving the way for better diagnosis and treatment. Three representatives from TMA participated in this effort, bringing patient voices to this cutting-edge method for shaping the future of autoimmune disease studies. Read the full article here: https://lnkd.in/dMUD6P2G #Myositis #MyositisWarrior #MyositisAwareness #TheMyositisAssociation #MyositisSupport #RareDisease #MYOMovement #MyositisLife #MyTMA #PatientAdvocacy #TheMyositisAgenda
-
-
📢 Exciting Update from #MDSCongress2024! We're thrilled to share our preliminary findings on the efficacy of smartphone-based at-home testing for sensitively tracking disease progression in #ParkinsonsDisease, even when participants are on stable dopaminergic therapy. Key contributors to this research include: Florian Lipsmeier, Stefan Lambrecht, Stefan Frässle, Yulia Gazizova, Damian Kwaśny, Bernhard Fehlmann, Thomas Kustermann, Michael Lindemann, Werner Popp, Kirsten Taylor, and Ron Postuma. 📍 Want to learn more? Visit our poster session at the congress (Sunday 29/9), or Contact me directly for detailed insights. #DigitalHealth #DigitalBiomarkers #ParkinsonsResearch
-
-
Kapil Raina, Brian Williams, and Chris Zealey share launch planning best practices for rare disease therapies, including budgeting, resource allocation, and stakeholder engagement strategies: https://lnkd.in/eSa2tdzX #AskHerspiegel #CommercialConversation #RareDisease #LaunchPlan
-
-
First-to-market rare disease therapies demand strategic planning and collaboration. Unlock key insights on driving awareness, educating providers, and enhancing access. Hear from our experts Emily Phillips and Ryan Subhan, MBA: https://lnkd.in/eTvsWpuW #MarketAccess #LaunchExcellence #AskHerspiegel
-
-
First-to-market rare disease therapies demand strategic planning and collaboration. Unlock key insights on driving awareness, educating providers, and enhancing access. Hear from our experts Emily Phillips and Ryan Subhan, MBA: https://bit.ly/3ZBNHxT #MarketAccess #LaunchExcellence #AskHerspiegel
-
-
Discover how patient collaboration can transform market access strategies for rare disease treatments: https://lnkd.in/gz2Ti-HH In this interview, Annabel de Maria Bosch, Chief Patient Officer, and Pepi Hurtado-Lopez, Managing Partner, Market Access & Pricing, share insights on co-creating strategies that ensure patients receive the treatments they need.
-
-
Medical Doctor with a Drive to Integrate Wearable Tech into Chronic Disease Management and Prevention | Empowering Adults to Live Healthier and Longer Lives
Exciting news in the journey toward truly personalized healthcare! Truveta's $320M funding and groundbreaking Genome Project mark a major step in understanding the interplay of genetics and health at an unprecedented scale. This initiative holds the promise of advancing precision medicine and transforming early detection and prevention efforts. #HealthcareInnovation #PrecisionMedicine #Genomics
New 🦄 sighting in Seattle! Health data company Truveta raised $320 million, pushing its valuation past $1 billion, to fuel an ambitious new initiative to create a giant genomic dataset. "When we have this data, we will finally begin to address the cost of healthcare through early detection and prevention rather than chasing the never-ending challenges of chronic disease management," said Truveta CEO Terry Myerson. "The impact will be profound." Read more: https://lnkd.in/d4b9kiH9
-
